{"nctId":"NCT03362931","briefTitle":"Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma","startDateStruct":{"date":"2018-07-19","type":"ACTUAL"},"conditions":["Glaucoma","Angle-Closure"],"count":65,"armGroups":[{"label":"XEN45 Glaucoma Treatment System (hereafter referred to as XEN)","type":"EXPERIMENTAL","interventionNames":["Device: XEN45"]}],"interventions":[{"name":"XEN45","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion Criteria: - Diagnosis of ACG defined as areas of iridotrabecular contact present in â‰¥ 2 quadrants and glaucomatous damage to optic disc and visual field, in the study eye - Study eye has healthy, free, and mobile conjunctiva in the target quadrant Exclusion Criteria: - Uncontrolled systemic disease (eg, diabetes, hypertension) - Known history of bleeding disorder or prolonged bleeding after surgery or those on pharmacologic blood thinners other than aspirin (up to 100 mg/day) - History of dermatologic keloid formation - Open angle glaucoma, active acute angle closure attack, congenital glaucoma, juvenile glaucoma, secondary glaucoma in the study eye - History of following surgeries in the study eye: o incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions o corneal graft including partial grafts such as Descemet's stripping endothelial keratoplasty and Descemet's membrane endothelial keratoplasty o previous laser or incisional intraocular surgery that might interfere with the outcome of this trial - Previous glaucoma shunt implantation in the target quadrant in the study eye - Active or history of chronic uveitis in the study eye - Unable to discontinue contact lens wear in the study eye during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving at Least a 20% Reduction From Baseline Hour 0 IOP While on the Same Number or Fewer IOP Lowering Medications at Month 12","description":"IOP will be measured using a Goldmann applanation tonometer","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline the Number of Concomitant IOP-lowering Medications","description":"The number of concomitant IOP-lowering medications following implantation will be compared with the number prior to implantation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.33"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":62},"commonTop":["INTRAOCULAR PRESSURE INCREASED","CONJUNCTIVAL HYPERAEMIA","CONJUNCTIVAL HAEMORRHAGE","CONJUNCTIVAL OEDEMA","VISUAL ACUITY REDUCED"]}}}